Clinical trial reveals acceptable safety and antimyeloma activity of venetoclax in relapsed or refractory t(11;14) multiple myeloma, indicating a viable targeted therapy option.
Key Points Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile in patients with relapsed/refractory MM. Venetoclax monotherapy has demonstrated antimyeloma activity in patients with relapsed/refractory MM positive for t(11;14).
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: